Abstract
This chapter describes the conceptual basis of a novel form of cancer therapy that we have developed, which uses structural components of the stroma of a tumor as an anchor and launchpad for disseminating chemotherapeutic agents within a tumor. It also utilizes a phenomenon called the Enhanced Permeability and Retention (EPR) effect, described in this chapter and elsewhere in this book, to localize and concentrate the effect of the therapy on the lesion and minimize damage to healthy organs. We refer to this combined strategy as cancer (CA) stroma (S) targeting (T), CAST therapy. The concept of CAST therapy is that stroma-targeting immunconjugates extravasate selectively from tumor vessels (but not from normal counterparts), due to the EPR effect, bind to the stroma to create a scaffold, from which sustained release of cytotoxic agents occurs and subsequently diffuse throughout the tumor tissue to damage both tumor cells and tumor vessels. Various anticancer agents, gene-delivery systems, and monoclonal antibody (mAb)-based therapies have been produced, based on the enhanced permeability and retention (EPR) effect, but the current combination of EPR with cancer stroma targeting for delivery of a drug is original and new. As one example to illustrate how we utilize the CAST concept, we present a version using an antibody to insoluble fibrin. We have reported that hemorrhage caused by cancer erosion can induce fibrin clot formation that creates a mass of insoluble fibrin (IF) in the tumor stroma. Along with that, Influx of fibroblasts and inflammatory cells into the tumor tissue also occurs. Consequently, most cancers possess a fibrin-rich stroma that hinders the distribution of macromolecules, including antibody-drug conjugates (ADCs). Therefore, the EPR effect is not clinically and efficiently functioning in such situations. We have developed an anti-IF mAb that does not react with fibrinogen or soluble fibrin and have successfully created and optimized anti-IF ADCs. An ADC is an anti-IF antibody conjugated with monomethyl auristatin E (MMAE), a potent microtubule inhibitor, via a Val-Leu-Lys linker that is severed specifically by plasmin (PLM). Free MMAE is only released when the IF- ADC is bound to the epitopes in the IF because plasmin is only active on IF and is neutralized by the innate α2-plasmin inhibitor circulating in the blood. Free MMAE may therefore easily reach cancer cells by diffusing through the stromal barrier. MMAE released from IF-ADC may also attack the tumor vascular endothelial cells resulting in tumor necrosis.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387–6392
Duncan R (2003) The dawning era of polymer therapeutics. Natl Rev 2:347–360
Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2:751–760
Matsumura Y, Kataoka K (2009) Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci 100:572–579
Hosokawa S, Tagawa T, Niki H, Hirakawa Y, Nohga K, Nagaike K (2003) Efficacy of immunoliposomes on cancer models in a cell-surface-antigen-density-dependent manner. Brit J Cancer 89:1545–1551
Hamaguchi T, Matsumura Y, Nakanishi Y, Muro K, Yamada Y, Shimada Y, Shirao K, Niki H, Hosokawa S, Tagawa T, Kakizoe T (2004) Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts. Cancer Sci 95:608–613
Matsumura Y, Gotoh M, Muro K, Yamada Y, Shirao K, Shimada Y, Okuwa M, Matsumoto S, Miyata Y, Ohkura H, Chin K, Baba S, Yamao T, Kannami A, Takamatsu Y, Ito K, Takahashi K (2004) Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol 15:517–525
Matsumura Y (2012) Cancer stromal targeting (CAST) therapy. Adv Drug Deliv Rev 64:710–719
Matsumura Y, Kimura M, Kato H, Yamamoto T, Maeda H (1989) In: Kinins V, Abe K, Moriya H, Fujii S (eds) Quantification, isolation and structural determination of bradykinin and hydroxyprolyl-bradykinin in tumor ascites. Plenum Publishing, New York, pp 587–592
Maeda H, Matsumura Y, Kato H (1988) Purification and identification of (Hydroxyprolyl3) bradykinin in ascitic fluid from a patient with gastric cancer. J Biol Chem 263:16051–16054
Matsumura Y, Kimura M, Yamamoto T, Maeda H (1988) Involvement of the kinin-generating cascade and enhanced vascular permeability in tumor tissue. Jpn J Cancer Res 79:1327–1334
Senger DR, Galli SJ, Dvorak AM, Peruzzi CA, Harvey VS, Dvorak HF (1983) Tumor cells secret a vascular permeability factor that promotes accumulation of ascites fluid. Science 21:983–985
Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391–400
Dvorak HF, Rickles FR (2006) Malignancy and hemostasis. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldharber SZ (eds) Hemostasis and thrombosis: basic principles and clinical practice, 5th edn. LippinCott Williams $ Wilkins, Philadelphia, pp 851–873
Bussard KM, Mutkus L, Stumpf K, Gomez-Manzano C, Marini FC (2016) Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Res 18:84
Nielsen MF, Mortensen MB, Detlefsen S (2016) Key players in pancreatic cancer-stroma interaction: cancer-associated fibroblasts, endothelial and inflammatory cells. World J Gastroenterol 22:2678–2700
Brown LF, Dvorak AM, Dvorak HF (1989) Leaky vessels, fibrin deposition, and fibrosis: a sequence of events common to solid tumors and to many other types of disease. Am Rev Respir Dis 140:1104–1107
Busuttil SJ, Ploplis VA, Castellino FJ, Tang L, Eaton JW, Plow EF (2004) A central role for plasminogen in the inflammatory response to biomaterials. J Thromb Haemost 2:1798–1805
Sawai T, Tomono K, Yanagihara K, Yamamoto Y, Kaku M, Hirakata Y, Koga H, Tashiro T, Kohno S (1997) Role of coagulase in a murine model of hematogenous pulmonary infection induced by intravenous injection of Staphylococcus aureus enmeshed in agar beads. Infect Immun 65(2):466–471
Trousseau A (1865) Pegmasia alba dolens, vol 3. Balliere JB et Fils, Paris
Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE (2006) Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 119:60–68
Kano MR, Bae Y, Iwata C, Morishita Y, Yashiro M, Oka M, Fujii T, Komuro A, Kiyono K, Kaminishi M, Hirakawa K, Ouchi Y, Nishiyama N, Kataoka K, Miyazono K (2007) Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc Natl Acad Sci 104:3460–3465
Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Rückert F, Grützmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Iacobuzio-Donahue C, Griffiths J, Tuveson DA (2009) Inhibition of hedgehog signalling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324:1457–1461
Thompson CB, Shepard HM, O’Connor PM, Kadhim S, Jiang P, Osgood RJ, Bookbinder LH, Li X, Sugarman BJ, Connor RJ, Nadjsombati S, Frost GI (2010) Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Ther 9:3052–3064
Unezaki S, Maruyama K, Hosoda J, Magae I, Koyanagi Y, Nakata M, Ishida O, Iwatsuru M, Tsuchiya S (1996) Direct measurement of the extravasation of polyethyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence microscopy. Int J Pharm 144:11–17
Tsukioka Y, Matsumura Y, Hamaguchi T, Koike H, Moriyasu F, Kakizoe T (2002) Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil). Jpn J Cancer Res 93:1145–1153
Yasunaga M, Manabe S, Tarin D, Matsumura Y (2011) Cancer-stroma targeting therapy by cytotoxic immunoconjugate bound to the collagen 4 network in the tumor tissue. Bioconjug Chem 22:1776–1783
Yasunaga M, Manabe S, Matsumura Y (2011) New concept of cytotoxic immunoconjugate therapy targeting cancer-induced fibrin clots. Cancer Sci 102:1396–1402
Bala V, Rao S, Boyd BJ, Prestidge CA (2013) Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38. J Control Release 172:48–61
Gebleux R, Stringhini M, Casanova R, Soltermann A, Neri D (2018) Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix. Int J Cancer 140:1670–1679
Hisada Y, Yasunaga M, Hanaoka S, Saijou S, Sugino T, Tsuji A, Saga T, Tsumoto K, Manabe S, Kuroda J, Kuratsu J, Matsumura Y (2013) Discovery of an uncovered region in fibrin clots and its clinical significance. Matsumura Y Sci Rep 3:2604–2610
Fuchigami H, Manabe S, Yasunaga M, Matsumura Y (2018) Chemotherpy payload of anti-insoluble fibrin antibody-drug conjugate is released specifically upon binding to fibrin. Sci Rep 8:14211
Lerch K, Leng C, Pinto A, Linkesch W, Sill H, Linden O, Andreas Viardot A, Keller U, Hess G, Lastoria S, Frigeri F, Neik N, Pott C, Scholz CW, Pezzutto A (2016) 90Yttrium-Ibritumomab Tiuxetan as first line treatment for follicular non-Hodgkin lymphoma. 5 year results from an international multicenter phase II clinical trial. Blood 128:1806
Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, Regan D, Kison P, Fisher S, Kroll S, Wahl RL (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352(5):441–449
Larson JA, Carrasquillo JA, Cheung NV, Press O (2015) Radioimmunotherapy of human tumours. Nat Rev Cancer 15:347–360
Pardoll DM (2012) Immunology beats cancer: a blueprint for successful translation. Nat Immunol 13(12):1129–1132
Cook AM, Lesterhuis WJ, Nowak AK, Lake RA (2016) Chemotherapy and immunotherapy: mapping the road ahead. Curr Opin Immunol 39:23–29
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Japan KK, part of Springer Nature
About this chapter
Cite this chapter
Matsumura, Y. (2019). Principle of CAST Strategy. In: Matsumura, Y., Tarin, D. (eds) Cancer Drug Delivery Systems Based on the Tumor Microenvironment. Springer, Tokyo. https://doi.org/10.1007/978-4-431-56880-3_11
Download citation
DOI: https://doi.org/10.1007/978-4-431-56880-3_11
Published:
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-56878-0
Online ISBN: 978-4-431-56880-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)